Table 4.

Clinical risk factors for SSEs in two groups

	Denosumab		ZA
Risk factors	HR(95%CI)	P –value	HR(95%CI)	P - value
Age (y)		0.003*		0.001*
≤60	1		1
> 60	3.13(1.02–1.68)		4.72(2.36–7.17)
Menopause age(y)		0.440		0.247
≤50	5.04(0.03–22.12)		5.04(0.03–22.12)
> 50	1		1
PHF		0.002*		0.005*
no	1		1
yes	21.34(5.23–49.12)		36.75(2.39–74.32)
FHF		0.037*		0.041*
no	1		1
yes	6.79(1.10–11.65)		8.86(1.43–38.15)
BMI(kg/m2)		0.793		0.219
≤19	3.76(0.66–31.32)		5.36(0.19–44.61)
> 19	1		1

^* Statistically significant values. SSEs: symptomatic skeletal events; ZA: zoledronic acid; PHF: personal history of fractures; FHF: family history of fractures; BMI: body mass index